Display options
Cite
Aghahowa SE, Ozolua RI, Bafor EE, et al. Toxicological effect of Artemisinin-Based Combination Therapies plus Paracetamol in malaria patients. Toxicol Rep. 2021;8:1930-1936doi: 10.1016/j.toxrep.2021.11.007.
Aghahowa, S. E., Ozolua, R. I., Bafor, E. E., Obarisiagbon, P., & Isah, A. O. (2021). Toxicological effect of Artemisinin-Based Combination Therapies plus Paracetamol in malaria patients. Toxicology reports, 81930-1936. https://doi.org/10.1016/j.toxrep.2021.11.007
Aghahowa, S E, et al. "Toxicological effect of Artemisinin-Based Combination Therapies plus Paracetamol in malaria patients." Toxicology reports vol. 8 (2021): 1930-1936. doi: https://doi.org/10.1016/j.toxrep.2021.11.007
Aghahowa SE, Ozolua RI, Bafor EE, Obarisiagbon P, Isah AO. Toxicological effect of Artemisinin-Based Combination Therapies plus Paracetamol in malaria patients. Toxicol Rep. 2021 Nov 25;8:1930-1936. doi: 10.1016/j.toxrep.2021.11.007. eCollection 2021. PMID: 34926171; PMCID: PMC8649067.
Copy Download .nbib Format: NLM
Share it on

Toxicol Rep. 2021 Nov 25;8:1930-1936. doi: 10.1016/j.toxrep.2021.11.007. eCollection 2021.

Toxicological effect of Artemisinin-Based Combination Therapies plus Paracetamol in malaria patients.

Toxicology reports

S E Aghahowa, R I Ozolua, E E Bafor, P Obarisiagbon, A O Isah

Affiliations

  1. Department of Pharmacology and Toxicology, University of Benin, Benin City, Nigeria.
  2. College of Medicine, University of Benin, Benin City, Nigeria.

PMID: 34926171 PMCID: PMC8649067 DOI: 10.1016/j.toxrep.2021.11.007

Abstract

BACKGROUND: Following the paucity of safety reports in the use of Artemisinin-Based Combination Therapies (ACTs) plus paracetamol, the study assessed safety potential of artemether-lumefantrine (ALP), artesunate-amodiaquine (AAP), artesunate-mefloquine (AMP), artesunate-sulphadoxine-pyrimethamine (ASPP) and dihydroartemisinin-piperaquine (DHPP) combination with paracetamol in malaria patients.

METHODS: ACTs and paracetamol were administered concomitantly in conventional doses/regimen to randomly selected patients. Blood samples were collected from the ante-cubital vein before and after completion of therapies. Toxicity markers such as weights, glucose, lipids, renal electrolytes, liver enzymes and haematological indices were assessed using standard protocols.

RESULTS: The total numbers of participants were 57 patients. Male to female ratio was 1:1.1. Mean body weight and ages were 59.19 ± 1.39 kg and 42.86 ± 1.32 years respectively. The mean temperatures prior to and after therapy were 37.49 ± 1.02 °C and 37.50 ± 0.17 °C respectively. Mean parasitaemia before the commencement of therapy was 6282 ± 21.01 parasites/μl. Out of thirty-seven toxicological indices evaluated, twenty-four were significantly altered by ACTs plus paracetamol (

CONCLUSION: Since ACTs plus paracetamol altered human system, discrete selection is essential in managing uncomplicated malaria most especially in patients with co-morbid conditions.

© 2021 The Author(s).

Keywords: ACTs; Malaria; Paracetamol; Safety

Conflict of interest statement

The authors report no declarations of interest.

References

  1. Indian J Pharm Sci. 2010 May;72(3):283-9 - PubMed
  2. Int J Nephrol. 2012;2012:465897 - PubMed
  3. JAMA. 2002 Nov 27;288(20):2579-88 - PubMed
  4. Drug Metab Rev. 1992;24(3):367-407 - PubMed
  5. Parasitol Int. 2008 Dec;57(4):490-4 - PubMed
  6. Pharmacogenomics. 2014;15(15):1931-40 - PubMed
  7. BJU Int. 2007 Nov;100(5):1172-5 - PubMed
  8. Ann Trop Med Parasitol. 2008 Mar;102(2):103-18 - PubMed
  9. Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):181-92 - PubMed
  10. J Hypertens. 2005 Nov;23(11):1931-7 - PubMed
  11. Lancet. 2010 May 8;375(9726):1634-9 - PubMed
  12. Anal Chem. 2006 Feb 1;78(3):743-52 - PubMed
  13. Infect Dis Rep. 2011 May 27;3(1):e8 - PubMed
  14. J Pharmacol Exp Ther. 2002 Feb;300(2):399-407 - PubMed
  15. Br J Nutr. 1997 Nov;78(5):751-60 - PubMed
  16. Am J Perinatol. 2008 Nov;25(10):617-22 - PubMed
  17. Parasitol Today. 1994 May;10(5):193-6 - PubMed
  18. Drug Saf. 2013 Sep;36(9):747-56 - PubMed
  19. Trans R Soc Trop Med Hyg. 1998 Jan-Feb;92(1):54-6 - PubMed
  20. Lancet Infect Dis. 2009 Dec;9(12):760-74 - PubMed
  21. JAMA. 2007 Aug 15;298(7):786-98 - PubMed
  22. Br J Haematol. 2002 Dec;119(3):839-47 - PubMed
  23. Histochem Cell Biol. 2004 Oct;122(4):333-8 - PubMed
  24. ISRN Trop Med. 2013;2013:1-9 - PubMed
  25. Niger J Physiol Sci. 2009 Dec;24(2):101-6 - PubMed
  26. Lancet. 1997 Sep 6;350(9079):704-9 - PubMed
  27. Lancet. 1986 Feb 22;1(8478):411-4 - PubMed
  28. Curr Microbiol. 2011 Jun;62(6):1739-42 - PubMed
  29. Mol Cell Biochem. 2007 Mar;297(1-2):131-8 - PubMed
  30. Nature. 2001 Dec 13;414(6865):813-20 - PubMed
  31. Curr Opin Mol Ther. 2009 Dec;11(6):632-40 - PubMed
  32. Paediatr Anaesth. 2008 Oct;18(10):915-21 - PubMed
  33. J Postgrad Med. 2003 Jul-Sep;49(3):218-20; discussion 221 - PubMed
  34. Malar J. 2009 Oct 12;8 Suppl 1:S6 - PubMed
  35. Ann Trop Paediatr. 1988 Dec;8(4):250-8 - PubMed
  36. Malar J. 2010 Dec 13;9 Suppl 3:S4 - PubMed
  37. Int J Exp Pathol. 2011 Jun;92(3):202-10 - PubMed
  38. Lancet. 2012 Aug 11;380(9841):572-80 - PubMed
  39. J Nutr. 2000 Jul;130(7):1724-33 - PubMed
  40. Am J Trop Med Hyg. 2004 Jan;70(1):8-14 - PubMed
  41. Eur J Clin Pharmacol. 2008 Jul;64(7):683-90 - PubMed
  42. Diabetes. 2005 Jun;54(6):1615-25 - PubMed
  43. Reprod Toxicol. 2006 Jan;21(1):83-93 - PubMed
  44. Ann Intern Med. 2002 Apr 16;136(8):604-15 - PubMed

Publication Types